284 related articles for article (PubMed ID: 24710689)
21. Vemurafenib (Zelboraf) with longer follow-up. Metastatic melanoma: a few extra months of life, but many adverse effects.
Prescrire Int; 2015 Apr; 24(159):89-90. PubMed ID: 25941696
[TBL] [Abstract][Full Text] [Related]
22. The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors.
Kaplan FM; Mastrangelo MJ; Aplin AE
J Invest Dermatol; 2010 Nov; 130(11):2669-71. PubMed ID: 20574441
[No Abstract] [Full Text] [Related]
23. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
24. Toxic epidermal necrolysis induced by vemurafenib.
Lapresta A; Dotor A; González-Herrada C
Actas Dermosifiliogr; 2015 Oct; 106(8):682-3. PubMed ID: 26051238
[No Abstract] [Full Text] [Related]
25. Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF(V) (600) mutations.
Yamazaki N; Kiyohara Y; Sugaya N; Uhara H
J Dermatol; 2015 Jul; 42(7):661-6. PubMed ID: 25884515
[TBL] [Abstract][Full Text] [Related]
26. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
[TBL] [Abstract][Full Text] [Related]
27. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
Dabner M; Harvey NT; Soma A; Wood BA
Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
[No Abstract] [Full Text] [Related]
28. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
Lang N; Weisser A; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
[No Abstract] [Full Text] [Related]
29. Vemurafenib and cutaneous adverse events--report of five cases.
Silva Gde B; Mendes AP; de Macedo MP; Pinto CA; Gibbons IL; Duprat Neto JP
An Bras Dermatol; 2015; 90(3 Suppl 1):242-6. PubMed ID: 26312729
[TBL] [Abstract][Full Text] [Related]
30. BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases.
Hui Ong EL; Sinha R; Jmor S; Fearfield L
Am J Dermatopathol; 2019 Mar; 41(3):214-217. PubMed ID: 30601209
[TBL] [Abstract][Full Text] [Related]
31. Vemurafenib-induced bilateral facial palsy.
Shailesh FN; Singh M; Tiwari U; Hutchins LF
J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
[TBL] [Abstract][Full Text] [Related]
32. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
Starz H; Gutschi M; Welzel J; Haas C
J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
[No Abstract] [Full Text] [Related]
33. Eosinophilic Infiltrates in Vemurafenib-Associated Verrucous Keratoses.
Longhurst WD; Honda K; Koon HB; Gerstenblith MR
Am J Dermatopathol; 2016 Oct; 38(10):766-8. PubMed ID: 27533075
[No Abstract] [Full Text] [Related]
34. [BRAF mutation detection in metastatic melanoma].
Dietel M; Enk A; Lehmann A; Bauer J; Garbe C; Kellner U; Kirchner T; Jung A; Kreipe H; Merkelbach-Bruse S; Büttner R; Rüschoff J; Schlake W; Schirmacher P; Penzel R; Stadler R
Pathologe; 2012 Jul; 33(4):352-6. PubMed ID: 22692278
[No Abstract] [Full Text] [Related]
35. BRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma.
Garrido MC; Gutierrez C; Riveiro-Falkenbach E; Ortiz P; Rodriguez-Peralto JL
Am J Dermatopathol; 2015 Oct; 37(10):795-8. PubMed ID: 26381028
[TBL] [Abstract][Full Text] [Related]
36. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib.
Sinha R; Edmonds K; Newton-Bishop J; Gore M; Larkin J; Fearfield L
J Clin Oncol; 2013 Jul; 31(19):e320-1. PubMed ID: 23715570
[No Abstract] [Full Text] [Related]
37. [New treatment options for metastatic melanoma].
Tietze JK; Berking C
Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
[No Abstract] [Full Text] [Related]
38. Haemorrhage due to proteolysis of FXIII and hyperfibrinolysis under vemurafenib treatment of metastatic melanoma.
Trappe R; Budde U; Zimmermann H
Thromb Haemost; 2012 Oct; 108(4):798-800. PubMed ID: 22918265
[No Abstract] [Full Text] [Related]
39. Vemurafenib-induced panniculitis.
Villani AP; Zaharia D; Dalle S; Depaepe L; Balme B; Thomas L
Eur J Dermatol; 2013 Apr; 23(2):258-60. PubMed ID: 23567624
[No Abstract] [Full Text] [Related]
40. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
